Resource Summary Report

Generated by NIF on Sep 7, 2026

OVCAR-4

RRID:CVCL_1627
Type: Cell Line

Proper Citation

RRID:CVCL_1627

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1627

Proper Citation: RRID:CVCL_1627

Description: Cell line OVCAR-4 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: High grade ovarian serous adenocarcinoma

Defining Citation: PMID:1348364, PMID:2041050, PMID:2307530, PMID:3335022, PMID:3930572, PMID:6372095, PMID:6385258, PMID:7718330, PMID:9041185, PMID:9331090, PMID:10700174, PMID:12080474, PMID:12960427, PMID:15748285, PMID:17088437, PMID:19372543, PMID:20164919, PMID:22068913, PMID:22336246, PMID:22347499, PMID:22384151, PMID:22460905, PMID:22628656, PMID:23839242, PMID:23856246, PMID:23933261, PMID:24023729, PMID:24279929, PMID:24670534, PMID:25485619, PMID:25877200, PMID:25984343, PMID:26589293, PMID:27235858, PMID:27377824, PMID:27397505, PMID:27807467, PMID:28196595, PMID:30894373, PMID:30971826, PMID:31068700, PMID:31733513, PMID:31978347, PMID:32612269, PMID:35839778, PMID:35918200, PMID:38861359

Comments: Population: Caucasian., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JFCR39 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: OVCAR-4

Synonyms: OVCAR 4, NIH:OVCAR-4, NIH:OVCAR4, OVCAR.4, OVCAR4, Ovcar4

Cross References: BTO:BTO_0002561, CLO:CLO_0037096, EFO:EFO_0005442, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioSample:SAMN03472889, BioSample:SAMN10987768, cancercelllines:CVCL_1627, Cell_Model_Passport:SIDM00092, ChEMBL-Cells:CHEMBL3307517, ChEMBL-Targets:CHEMBL614051, Cosmic:688105, Cosmic:875860, Cosmic:897434, Cosmic:905990, Cosmic:974295, Cosmic:1044240, Cosmic:1092624, Cosmic:1175884, Cosmic:1305313, Cosmic:1312355, Cosmic:1436034, Cosmic:1998466, Cosmic-CLP:905990, DepMap:ACH-000617, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:905990, GEO:GSM2174, GEO:GSM50220, GEO:GSM50284, GEO:GSM185137, GEO:GSM185138, GEO:GSM186442, GEO:GSM186443, GEO:GSM743475, GEO:GSM743494, GEO:GSM750829, GEO:GSM784572, GEO:GSM799364, GEO:GSM799427, GEO:GSM844669, GEO:GSM844670, GEO:GSM847107, GEO:GSM851935, GEO:GSM887484, GEO:GSM888565, GEO:GSM1153436, GEO:GSM1181279, GEO:GSM1181286, GEO:GSM1374801, GEO:GSM1670318, GEO:GSM2124646, IARC_TP53:21085, IARC_TP53:21126, IARC_TP53:30217, LiGeA:CCLE_876, LINCS_LDP:LCL-1697, Millipore:SCC258, NCI-DTP:OVCAR-4, PharmacoDB:OVCAR4_1218_2019, PRIDE:PXD003539, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD030304, Progenetix:CVCL_1627, PubChem_Cell_line:CVCL_1627, SKY/M-FISH/CGH:2817, Wikidata:Q54937010

ID: CVCL_1627

Record Creation Time: 20220427T221403+0000

Record Last Update: 20260905T182007+0000

Ratings and Alerts

No rating or validation information has been found for OVCAR-4.

No alerts have been found for OVCAR-4.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 53 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Gendrau-Sanclemente N, et al. (2026) Sphingosine-1-Phosphate Receptor 1 Promotes Ovarian Cancer Tumorsphere Proliferation and Metastasis. International journal of cancer, 159(3), 768.

Saleh A, et al. (2026) CCDC80 suppresses high-grade serous ovarian cancer migration via negative regulation of B7-H3. Molecular oncology.

Yamamoto TM, et al. (2026) Chromobox 2 Inhibition: A Novel Activity of Alisertib, an Aurora A Kinase Inhibitor. Molecular cancer therapeutics, 25(7), 1130.

Jorgensen A, et al. (2026) Tumor-Infiltrating Nociceptor Neurons in Ovarian Cancer Treatment Resistance. Advanced biology, 10(3), e00404.

Sun S, et al. (2026) CBX2 phase-separation contributes to homologous recombination repair and drug resistance in ovarian cancer. Cell death & disease, 17(1).

Gao Y, et al. (2026) DYRK1B Inhibition by AZ191 Sensitizes High-Grade Serous Ovarian Cancer to Niraparib Through Promoting Apoptosis and Ferroptosis. Biomedicines, 14(4).

Nathan N, et al. (2026) Tumor-draining lymph nodes in ovarian cancer lack germinal centers but harbor tumor-reactive memory B cells clonally linked to intra-tumoral B cells. Immunity, 59(6), 1743.

Kimmel GJ, et al. (2026) Universal principles of cell population growth follow from local contact inhibition. iScience, 29(6), 115953.

Woodruff ER, et al. (2025) Ablation of hematopoietic stem cell derived adipocytes reduces tumor burden in syngeneic mouse models of high-grade serous carcinoma. bioRxiv : the preprint server for biology.

Cheng YY, et al. (2025) Loss of Predicted Cell Adhesion Molecule MPZL3 Promotes EMT in Ovarian Cancer. Cancer research communications, 5(7), 1180.

Kenny HA, et al. (2025) Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth. Molecular cancer therapeutics, 24(8), 1252.

Doro Pereira L, et al. (2025) PARP Inhibitors Differentially Regulate Immune Responses in Distinct Genetic Backgrounds of High-Grade Serous Tubo-Ovarian Carcinoma. Cancer research communications, 5(2), 339.

Hockings H, et al. (2025) Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control. Cancer research, 85(18), 3503.

Yuan S, et al. (2025) The protease ADAMTS5 controls ovarian cancer cell invasion, downstream of Rab25. The FEBS journal, 292(17), 4491.

Kim D, et al. (2025) Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers. NPJ precision oncology, 9(1), 3.

Mishra AK, et al. (2024) Targeting the GPI transamidase subunit GPAA1 abrogates the CD24 immune checkpoint in ovarian cancer. Cell reports, 43(4), 114041.

Kunkel MW, et al. (2024) HTS384 NCI60: The Next Phase of the NCI60 Screen. Cancer research, 84(15), 2403.

Zhang Y, et al. (2024) Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma. Cancer research communications, 4(12), 3165.

Spirtos AN, et al. (2024) RBN-2397, a PARP7 Inhibitor, Synergizes with Paclitaxel to Inhibit Proliferation and Migration of Ovarian Cancer Cells. bioRxiv : the preprint server for biology.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell chemical biology, 31(7), 1247.